COMMUNIQUÉS West-GlobeNewswire

-
NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
21/05/2019 -
Panel identifies interventions and preferred measures to advance antimicrobial stewardship
21/05/2019 -
SuperSonic Imagine Equips the Radiological Network of Romandy with 8 Aixplorer MACH 30 Ultrasound Systems
21/05/2019 -
Information regarding acquisition or disposal of a major holding
21/05/2019 -
Tauriga Sciences Inc. Now Accepting Pre-Orders for its Blood Orange Flavored CBD Infused Chewing Gum
21/05/2019 -
Q-Centrix Continues to Expand its Registry Reporting Inventory with General Thoracic Surgery Program Certification
21/05/2019 -
Axiom Real-Time Metrics Showcasing Fusion at Outsourcing in Clinical Trials East Coast 2019
21/05/2019 -
DRAFT RESOLUTIONS of Annual General Meeting of Shareholders of joint stock company “Grindeks” to be held on 04 June 2019
21/05/2019 -
CyberFuels Has Significant Increase in Revenue in Third Quarter of 2019
21/05/2019 -
Innovation Pharmaceuticals At Digestive Disease Week Conference, Nears Selecting Drug Formulation Company to Prepare Oral Brilacidin for Targeted Delivery in Ulcerative Colitis
21/05/2019 -
Sienna Biopharmaceuticals to Present at Dermatology Drug Development Summit Europe
21/05/2019 -
Molecular You Named a 2019 Gartner ‘Cool Vendor’ in Healthcare Artificial Intelligence
21/05/2019 -
Kannalife Inc. Publishes New Research on Chemotherapy-Induced Peripheral Neuropathy
21/05/2019 -
Predictive Technology Group Reports Third Quarter Fiscal 2019 Financial Results
21/05/2019 -
DiaMedica Therapeutics Announces Formation of Scientific Advisory Board for Kidney Disease
21/05/2019 -
Marrone Bio Innovations to Present at the 9th Annual LD Micro Invitational Investor Conference in Los Angeles on Tuesday, June 4th
21/05/2019 -
Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product
21/05/2019 -
Assure Holdings Sets First Quarter 2019 Conference Call for Wednesday, May 29, 2019, at 11:00 a.m. ET
21/05/2019 -
Bellerophon Presents Additional Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference
21/05/2019
Pages